Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy: Critical Reviews in Oncology/Hematology

S. Arcangeli; B.A. Jereczek-Fossa; F. Alongi; C. Aristei; C. Becherini; L. Belgioia; M. Buglione; L. Caravatta; R.M. D'Angelillo; A.R. Filippi; M. Fiore; D. Genovesi; C. Greco; L. Livi; S.M. Magrini; G. Marvaso; R. Mazzola; I. Meattini; A. Merlotti; I. Palumbo; S. Pergolizzi; S. Ramella; U. Ricardi; E. Russi; M. Trovò; A. Sindoni; V. Valentini; R. Corvò

doi:10.1016/j.critrevonc.2018.11.005

Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy: Critical Reviews in Oncology/Hematology

S. Arcangeli, B.A. Jereczek-Fossa, F. Alongi, C. Aristei, C. Becherini, L. Belgioia, M. Buglione, L. Caravatta, R.M. D'Angelillo, A.R. Filippi, M. Fiore, D. Genovesi, C. Greco, L. Livi, S.M. Magrini, G. Marvaso, R. Mazzola, I. Meattini, A. Merlotti, I. PalumboS. Pergolizzi, S. Ramella, U. Ricardi, E. Russi, M. Trovò, A. Sindoni, V. Valentini, R. Corvò

Research output: Contribution to journal › Article

Abstract

Over the past century, technologic advances have promoted the evolution of radiation therapy into a precise treatment modality allowing for the maximal administration of dose to tumors while sparing normal tissues. In parallel with this technological maturation, the rapid expansion in understanding the basic biology and heterogeneity of cancer has led to the development of several compounds that target specific pathways. Many of them are in advanced steps of clinical development for combination treatments with radiotherapy, and can be incorporated into radiation oncology practice for a personalized approach to maximize the therapeutic gain. This review describes the rationale for combining novel agents with radiation, and provides an overview of the current landscape focused on treatment efficacy. © 2018 Elsevier B.V.

Original language	English
Pages (from-to)	87-103
Number of pages	17
Journal	Crit. Rev. Oncol. Hematol.
Volume	134
DOIs	https://doi.org/10.1016/j.critrevonc.2018.11.005
Publication status	Published - 2019

Fingerprint

Keywords

abiraterone
anastrozole
antineoplastic agent
apalutamide
bevacizumab
capecitabine
cetuximab
cisplatin
docetaxel
enzalutamide
erlotinib
everolimus
exemestane
gemcitabine
imatinib
letrozole
nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor
oxaliplatin
paclitaxel
panitumumab
pertuzumab
sonidegib
sorafenib
sunitinib
temozolomide
trastuzumab
unindexed drug
veliparib
vemurafenib
vismodegib
radiosensitizing agent
basal cell carcinoma
brain metastasis
breast cancer
cancer combination chemotherapy
cancer control
cancer radiotherapy
cancer survival
carcinomatous peritonitis
clinical effectiveness
digestive system cancer
drug efficacy
drug safety
esophageal adenocarcinoma
gastrointestinal stromal tumor
glioblastoma
glioma
head and neck squamous cell carcinoma
human
human epidermal growth factor receptor 2 negative breast cancer
human epidermal growth factor receptor 2 positive breast cancer
kidney cancer
kidney metastasis
melanoma
metastatic breast cancer
metastatic colorectal cancer
muscle invasive bladder cancer
non small cell lung cancer
nonhuman
pancreas cancer
pancreas islet cell tumor
phase 2 clinical trial (topic)
phase 3 clinical trial (topic)
prostate cancer
rectum cancer
renal cell carcinoma
Review
solid malignant neoplasm
treatment failure
chemoradiotherapy
Italy
neoplasm
treatment outcome
Chemoradiotherapy
Humans
Neoplasms
Radiation-Sensitizing Agents
Treatment Outcome

Cite this

Arcangeli, S., Jereczek-Fossa, B. A., Alongi, F., Aristei, C., Becherini, C., Belgioia, L., Buglione, M., Caravatta, L., D'Angelillo, R. M., Filippi, A. R., Fiore, M., Genovesi, D., Greco, C., Livi, L., Magrini, S. M., Marvaso, G., Mazzola, R., Meattini, I., Merlotti, A., ... Corvò, R. (2019). Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy: Critical Reviews in Oncology/Hematology. Crit. Rev. Oncol. Hematol., 134, 87-103. https://doi.org/10.1016/j.critrevonc.2018.11.005

Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy : Critical Reviews in Oncology/Hematology. / Arcangeli, S.; Jereczek-Fossa, B.A.; Alongi, F.; Aristei, C.; Becherini, C.; Belgioia, L.; Buglione, M.; Caravatta, L.; D'Angelillo, R.M.; Filippi, A.R.; Fiore, M.; Genovesi, D.; Greco, C.; Livi, L.; Magrini, S.M.; Marvaso, G.; Mazzola, R.; Meattini, I.; Merlotti, A.; Palumbo, I.; Pergolizzi, S.; Ramella, S.; Ricardi, U.; Russi, E.; Trovò, M.; Sindoni, A.; Valentini, V.; Corvò, R.

In: Crit. Rev. Oncol. Hematol., Vol. 134, 2019, p. 87-103.

Research output: Contribution to journal › Article

Arcangeli, S, Jereczek-Fossa, BA, Alongi, F, Aristei, C, Becherini, C, Belgioia, L, Buglione, M, Caravatta, L, D'Angelillo, RM, Filippi, AR, Fiore, M, Genovesi, D, Greco, C, Livi, L, Magrini, SM, Marvaso, G, Mazzola, R, Meattini, I, Merlotti, A, Palumbo, I, Pergolizzi, S, Ramella, S, Ricardi, U, Russi, E, Trovò, M, Sindoni, A, Valentini, V & Corvò, R 2019, 'Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy: Critical Reviews in Oncology/Hematology', Crit. Rev. Oncol. Hematol., vol. 134, pp. 87-103. https://doi.org/10.1016/j.critrevonc.2018.11.005

Arcangeli S, Jereczek-Fossa BA, Alongi F, Aristei C, Becherini C, Belgioia L et al. Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy: Critical Reviews in Oncology/Hematology. Crit. Rev. Oncol. Hematol. 2019;134:87-103. https://doi.org/10.1016/j.critrevonc.2018.11.005

Arcangeli, S. ; Jereczek-Fossa, B.A. ; Alongi, F. ; Aristei, C. ; Becherini, C. ; Belgioia, L. ; Buglione, M. ; Caravatta, L. ; D'Angelillo, R.M. ; Filippi, A.R. ; Fiore, M. ; Genovesi, D. ; Greco, C. ; Livi, L. ; Magrini, S.M. ; Marvaso, G. ; Mazzola, R. ; Meattini, I. ; Merlotti, A. ; Palumbo, I. ; Pergolizzi, S. ; Ramella, S. ; Ricardi, U. ; Russi, E. ; Trovò, M. ; Sindoni, A. ; Valentini, V. ; Corvò, R. / Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy : Critical Reviews in Oncology/Hematology. In: Crit. Rev. Oncol. Hematol. 2019 ; Vol. 134. pp. 87-103.

@article{bcf66d60cb87463793ccce53db58db34,

title = "Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy: Critical Reviews in Oncology/Hematology",

abstract = "Over the past century, technologic advances have promoted the evolution of radiation therapy into a precise treatment modality allowing for the maximal administration of dose to tumors while sparing normal tissues. In parallel with this technological maturation, the rapid expansion in understanding the basic biology and heterogeneity of cancer has led to the development of several compounds that target specific pathways. Many of them are in advanced steps of clinical development for combination treatments with radiotherapy, and can be incorporated into radiation oncology practice for a personalized approach to maximize the therapeutic gain. This review describes the rationale for combining novel agents with radiation, and provides an overview of the current landscape focused on treatment efficacy. {\textcopyright} 2018 Elsevier B.V.",

keywords = "abiraterone, anastrozole, antineoplastic agent, apalutamide, bevacizumab, capecitabine, cetuximab, cisplatin, docetaxel, enzalutamide, erlotinib, everolimus, exemestane, gemcitabine, imatinib, letrozole, nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor, oxaliplatin, paclitaxel, panitumumab, pertuzumab, sonidegib, sorafenib, sunitinib, temozolomide, trastuzumab, unindexed drug, veliparib, vemurafenib, vismodegib, radiosensitizing agent, basal cell carcinoma, brain metastasis, breast cancer, cancer combination chemotherapy, cancer control, cancer radiotherapy, cancer survival, carcinomatous peritonitis, clinical effectiveness, digestive system cancer, drug efficacy, drug safety, esophageal adenocarcinoma, gastrointestinal stromal tumor, glioblastoma, glioma, head and neck squamous cell carcinoma, human, human epidermal growth factor receptor 2 negative breast cancer, human epidermal growth factor receptor 2 positive breast cancer, kidney cancer, kidney metastasis, melanoma, metastatic breast cancer, metastatic colorectal cancer, muscle invasive bladder cancer, non small cell lung cancer, nonhuman, pancreas cancer, pancreas islet cell tumor, phase 2 clinical trial (topic), phase 3 clinical trial (topic), prostate cancer, rectum cancer, renal cell carcinoma, Review, solid malignant neoplasm, treatment failure, chemoradiotherapy, Italy, neoplasm, treatment outcome, Chemoradiotherapy, Humans, Neoplasms, Radiation-Sensitizing Agents, Treatment Outcome",

author = "S. Arcangeli and B.A. Jereczek-Fossa and F. Alongi and C. Aristei and C. Becherini and L. Belgioia and M. Buglione and L. Caravatta and R.M. D'Angelillo and A.R. Filippi and M. Fiore and D. Genovesi and C. Greco and L. Livi and S.M. Magrini and G. Marvaso and R. Mazzola and I. Meattini and A. Merlotti and I. Palumbo and S. Pergolizzi and S. Ramella and U. Ricardi and E. Russi and M. Trov{\`o} and A. Sindoni and V. Valentini and R. Corv{\`o}",

note = "Export Date: 25 February 2020 CODEN: CCRHE Correspondence Address: Arcangeli, S.; Department of Radiation Oncology, Policlinico S. Gerardo and University of Milan “Bicocca”, Via Pergolesi 33, Monza (MB) – Italy, Italy; email: stefano.arcangeli@yahoo.it Chemicals/CAS: abiraterone, 154229-19-3; anastrozole, 120511-73-1; apalutamide, 956104-40-8; bevacizumab, 216974-75-3, 1438851-35-4; capecitabine, 154361-50-9; cetuximab, 205923-56-4; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; docetaxel, 114977-28-5; enzalutamide, 915087-33-1; erlotinib, 183319-69-9, 183321-74-6; everolimus, 159351-69-6; exemestane, 107868-30-4; gemcitabine, 103882-84-4; imatinib, 152459-95-5, 220127-57-1; letrozole, 112809-51-5; oxaliplatin, 61825-94-3; paclitaxel, 33069-62-4; panitumumab, 339177-26-3; sonidegib, 956697-53-3, 1218778-77-8; sorafenib, 284461-73-0; sunitinib, 341031-54-7, 557795-19-4; temozolomide, 85622-93-1; trastuzumab, 180288-69-1, 1446410-98-5; veliparib, 912444-00-9; vemurafenib, 918504-65-1; vismodegib, 879085-55-9; Radiation-Sensitizing Agents References: Ahmed, K.A., Stallworth, D.G., Kim, Y., Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy (2016) Ann. Oncol., 27, pp. 434-441; Amici, J.M., Beylot-Barry, M., Locally advanced basal-cell carcinoma: combined alternative treatments beyond surgery (2015) Ann. Chir. Plast. Esthet., 60, pp. 321-325; Ang, K.K., Zhang, Q., Rosenthal, D.I., Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522 (2014) J. Clin. Oncol., 32 (September (27)), pp. 2940-2950; Antonia, S.J., Villegas, A., Daniel, D., Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer (2017) N. Engl. J. Med., 377, pp. 1919-1929; Antonia, S.J., Villegas, A., Daniel, D., Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC (2018) N. Engl. J. Med.; Argiris, A., Heron, D.E., Smith, R.P., Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer (2010) J. Clin. Oncol., 28 (December (36)), pp. 5294-5300; Avallone, A., Pecori, B., Bianco, F., Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: results of the BRANCH trial (2015) Oncotarget., 6 (October (30)), pp. 30394-30407; Azria, D., Larbouret, C., Robert, B., Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials (2003) Bull. Cancer, 90, pp. S202-S212; Badache, A., Hynes, N.E., A new therapeutic antibody masks ErbB2 to its partners (2004) Cancer Cell, 5, pp. 299-301. , 27; Balana, C., De Las Penas, R., Sep{\'u}lveda, J.M., A multicenter randomized study comparing temozolomide (TMZ) versus TMZ-plus-bevacizumab (BEV) before standard treatment in unresectable glioblastoma (GBM) patients (p): the GENOM 009 study by the GEINO group (2014) J. Clin. Oncol., 32 (5s). , suppl; abstr 2028; Baroudjian, B., Boussemart, L., Routier, E., Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer? (2014) Eur. J. Dermatol., 24, pp. 265-267; Bartek, J., Mistrik, M., Bartkova, J., Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer (2013) Cancer Discov., 3, pp. 1222-1224; Basset-Seguin, N., Hauschild, A., Grob, J., Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial (2015) Lancet Oncol., 16, pp. 729-736; Baumann, M., Krause, M., Dikomey, E., EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms (2007) Radiother. Oncol., 83, pp. 238-248; Beer, T.M., Armstrong, A.J., Rathkopf, D.E., Enzalutamide in metastatic prostate cancer before chemotherapy (2014) N. Engl. J. Med., 371, pp. 424-433; Beaver, J.A., Park, B.H., The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer (2012) Future Oncol., 8 (June (6)), pp. 651-657; Belkac{\'e}mi, Y., Gligorov, J., Ozsahin, M., Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study (2008) Ann. Oncol., 19, pp. 1110-1116; Blumenschein, G.R., Jr, Paulus, R., Curran, W.J., Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324 (2011) J. Clin. Oncol., 29 (June (17)), pp. 2312-2318; Blaszkowsky, L.S., Ryan, D.P., Szymonifka, J., Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer (2014) Ann. Oncol., 25 (January (1)), pp. 121-126; Block, A.M., Alite, F., Diaz, A.Z., Combination trimodality therapy using vismodegib for basal cell carcinoma of the face (2015) Case Rep. Oncol. Med., 2015; Bonner, J.A., Harari, P.M., Giralt, J., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck (2006) N. Engl. J. Med., 354 (February (6)), pp. 567-578; Bradley, J.D., Paulus, R., Komaki, R., Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study (2015) Lancet Oncol., 16 (February (2)), pp. 187-199; Buglione, M., Maddalo, M., Corv{\`o}, R., Subgroup analysis according to human papillomavirus status and tumor site of a randomized phase II trial comparing cetuximab and cisplatin combined with radiation therapy for locally advanced head and neck Cancer (2017) Int. J. Radiat. Oncol. Biol. Phys., 97 (March (3)), pp. 462-472; Caffo, O., Maines, F., Donner, D., Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients (2014) Clin. Genitourin. Cancer, 12 (October (5)), pp. 312-316; Carmeliet, P., Jain, R.K., Angiogenesis in cancer and other diseases (2000) Nature., 407 (September (6801)), pp. 249-257; Ceolin Foletto, M., Haas, S.E., Cutaneous melanoma: new advances in treatment (2014) An. Bras. Dermatol., 89 (March-April (2)), pp. 301-310; Crane, C.H., Eng, C., Feig, B.W., Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer (2010) Int. J. Radiat. Oncol. Biol. Phys., 76 (March (3)), pp. 824-830; Crosby, T., Hurt, C.N., Falk, S., Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial (2013) Lancet Oncol., 14 (June (7)), pp. 627-637; Chalmers, A., PARP-1 PARP-2, and the cellular response to low doses of ionizing radiation (2004) Int. J. Radiat. Oncol. Biol. Phys., 58 (2), pp. 410-419; Chandra, R.A., Wilhite, T.J., Balboni, T.A., A systematic evaluation of abscopal responses following RT in metastatic melanoma patients treated with ipilimumab (2015) Oncoimmunology, 4 (11); Chang, A.L., Solomon, J.A., Hainsworth, J.D., Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib (2014) J. Am. Acad. Dermatol., 70, pp. 60-69; Chen, D.J., Nirodi, C.S., The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage (2007) Clin. Cancer Res., 13, pp. 6555-6560; Chen, S.W., Lin, L.C., Kuo, Y.C., Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma (2014) Int. J. Radiat. Oncol. Biol. Phys., 88 (5), pp. 1041-1047; Cheng, A.L., Kang, Y.K., Chen, Z., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial (2009) Lancet Oncol., 10 (1), pp. 25-34; Chinnaiyan, P., Huang, S., Vallabhaneni, G., Mechanisms ofenhanced radiation response following epidermal growth factorreceptor signaling inhibition by erlotinib (Tarceva) (2005) Cancer Res., 65 (8), pp. 3328-3335; Chinnaiyan, P., Won, M., Wen, P.Y., A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913 (2018) Neuro Oncol., 20 (April (5)), pp. 666-673; Chinot, O.L., Wick, W., Mason, W., Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma (2014) N. Engl. J. Med., 370, pp. 709-722; Cho, E., Mostaghel, E.A., Russell, K.J., External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens (2015) Int. J. Radiat. Oncol. Biol. Phys., 92 (June (2)), pp. 236-243; Cuneo, K.C., Geng, L., Fu, A., SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation (2008) Int. J. Radiat. Oncol. Biol. Phys., 71, pp. 873-879; de Melo, A.C., Grazziotin-Reisner, R., Erlich, F., A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I (2016) Cancer Chemother. Pharmacol., 78 (1), pp. 101-109; Dellas, K., H{\"o}hler, T., Reese, T., Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer (2013) Radiat. Oncol., 8 (April), p. 90; Detti, B., D'Angelillo, R.M., Ingrosso, G., Combining abiraterone and radiotherapy in prostate Cancer patients who progressed during abiraterone therapy (2017) Anticancer Res., 37 (July (7)), pp. 3717-3722; Deutsch, E., Le P{\'e}choux, C., Faivre, L., Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer (2015) Ann. Oncol., 26, pp. 1223-1229; Dipetrillo, T., Pricolo, V., Lagares-Garcia, J., Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer (2012) Int. J. Radiat. Oncol. Biol. Phys., 82 (January (1)), pp. 124-129; Dong, H., Strome, S.E., Salomao, D.R., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion (2002) Nat. Med., 8, pp. 793-800; Dwedney, A., Cunningham, D., Tabernero, J., Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C) (2012) J. Clin. Oncol., 30 (May (14)), pp. 1620-1627; Escudier, B., Eisen, T., Stadler, W.M., Sorafenib in advanced clear-cell renal-cell carcinoma (2007) N. Engl. J. Med., 356 (2), pp. 125-134; Ferrara, N., VEGF and the quest for tumour angiogenesis factors (2002) Nat. Rev. Cancer, 2 (10), pp. 795-803; Ferrarelli, L.K., Hormones in repair and resistance (2013) Sci. Signal., 6, p. 304. , pp.ec 293; Filippi, A.R., Fava, P., Badellino, S., Astrua, C., Ricardi, U., Quaglino, P., Radiotherapy and immune checkpoints inhibitors for advanced melanoma (2016) Radiother. Oncol., 120 (July (1)), pp. 1-12; Folkman, J., Tumor angiogenesis: therapeutic implications (1971) N. Engl. J. Med., (21), pp. 1182-1186; Fornaro, L., Caparello, C., Vivaldi, C., Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review (2014) World J. Gastroenterol., 20 (May (20)), pp. 6081-6091; Fizazi, K., Massard, C., James, N.D., ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: preclinical and phase I data (2013) Proc Am Soc Clin Oncol, 31. , abstr 65. 19; Fu, P., He, Y.S., Huang, Q., Bevacizumab treatment for newly diagnosed glioblastoma: systematic review and meta-analysis of clinical trials (2016) Mol. Clin. Oncol., 4 (May (5)), pp. 833-838; Fury, M.G., Lee, N.Y., Sherman, E., A phase I study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer (2013) Int. J. Radiat. Oncol. Biol. Phys., 87 (November (3)), pp. 479-486; Gani, C., Coackley, C., Kumareswaran, R., In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: an exploration of the therapeutic ratio (2015) Radiother. Oncol 2015, 116 (September (3)), pp. 486-494; Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Tumor response to radiotherapy regulated by endothelial cell apoptosis (2003) Science., 300 (May (5622)), pp. 1155-1159; Garcia-Barros, M., Moeller, B.J., Cao, Y., Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules (2004) Cancer Cell, 5 (May (5)), pp. 429-441; Gasparini, G., Torino, F., Ueno, T., A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer (2012) Angiogenesis., 15 (March (1)), pp. 141-150; Geoffrois, L., Martin, L., De Raucourt, D., Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas. Results of the GORTEC-02 phase III randomized trial (2018) J. Clin. Oncol., (July); Ghashghaei, M., Muanza, T., Paliouras, M., Niazi, T., Effect of enzalutamide on sensitivity in prostate cancer cells to radiation by inhibition of DNA double strand break repair (2017) J. Clin. Oncol., 35 (6_suppl). , 208-208; Gilbert, M.R., Dignam, J.J., Armstrong, T.S., A randomized trial of bevacizumab for newly diagnosed glioblastoma (2014) N. Engl. J. Med., 370, pp. 699-708; Giralt, J., Trigo, J., Nuyts, S., Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous cell carcinoma of the head and neck (CONCERT-2): a randomized controlled, open label phase 2 trial (2015) Lancet Oncol., 16 (February (2)), pp. 221-232; Goding, S.R., Wilson, K.A., Xie, Y., Restoring immune function of Tumor specific CD4 ﬂ T cells during recurrence of melanoma (2013) J. Immunol., 190, pp. 4899-4909; Golden, E.B., Demaria, S., Schiff, P.B., An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer (2013) Cancer Immunol. Res., 1, pp. 365-372; Gorski, D.H., Beckett, M.A., Jaskowiak, N.T., Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation (1999) Cancer Res., 59 (14), pp. 3374-3378; Govindan, R., Bogart, J., Stinchcombe, T., Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: cancer and Leukemia Group B trial 30407 (2011) J. Clin. Oncol., 29 (August (23)), pp. 3120-3125; Grimaldi, A.M., Simeone, E., Giannarelli, D., Abscopal effects of RT on advanced melanoma patients who progressed after ipilimumab immunotherapy (2014) Oncoimmunology, p. e28780. , 1-8; Gullick, W.J., Downward, J., Parker, P.J., The structure and function of the epidermal growth factor receptor studied by using antisynthetic peptide antibodies (1985) Proc. R. Soc. Lond., B, Biol. Sci., 226, pp. 127-134; Hainsworth, J.D., Spigel, D.R., Greco, F.A., Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium (2011) Cancer J., 17 (September-October (5)), pp. 267-272; Halyard, M.Y., Pisansky, T.M., Dueck, A.C., Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831 (2009) J. Clin. Oncol., 27, pp. 2638-2644; Hammel, P., Huguet, F., van Laethem, J.L., Effect of Chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic Cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial (2016) JAMA., 315 (May (17)), pp. 1844-1853; Hauschild, A., Grob, J.J., Demidov, L.V., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial (2012) Lancet., 380 (July (9839)), pp. 358-365; Helbling, D., Bodoky, G., Gautschi, O., Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07 (2013) Ann. Oncol., 24 (March (3)), pp. 718-725; Herchenhorn, D., Dias, F.L., Viegas, C.M., Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (2010) Int. J. Radiat. Oncol. Biol. Phys., 78 (November (3)), pp. 696-702; Herman, J.M., Fan, K.Y., Wild, A.T., Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer (2013) Int. J. Radiat. Oncol. Biol. Phys., 86 (July (4)), pp. 678-685; Hiniker, S.M., Chen, D.S., Reddy, S., A systemic complete response of metastatic melanoma to local radiation and immunotherapy (2012) Transl. Oncol., 5 (6), pp. 404-407; Hofheinz, R.D., Horisberger, K., Woernle, C., Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer (2006) Int. J. Radiat. Oncol. Biol. Phys., 66 (December (5)), pp. 1384-1390; Horton, J.K., Halle, J., Ferraro, M., Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial (2010) Int. J. Radiat. Oncol. Biol. Phys., 76 (March (4)), pp. 998-1004; Huang, S.M., Harari, P.M., Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis (2000) Clin. Cancer Res., 6, pp. 2166-2174; Clifford, A., Hudis, M.D., Trastuzumab—mechanism of action and use in clinical practice (2007) NEJM, 357 (1), pp. 39-51; Iyengar, P., Kavanagh, B.D., Wardak, Z., Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer (2014) J. Clin. Oncol., 32 (December (34)), pp. 3824-3830; Jacobsen, A.A., Strasswimmer, J., Spontaneous resolution of advanced basal cell carcinoma after short-pulse treatment with hedgehog pathway inhibitor (2016) JAAD Case Rep., 30 (2), pp. 360-361; Kao, J., Packer, S., Vu, H.L., Phase 1 study of concurrent sunitinib and image- guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response (2009) Cancer, 115 (August (15)), pp. 3571-3580; Kao, J., Chen, C.T., Tong, C.C., Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial (2014) Target. Oncol., 9 (June (2)), pp. 145-153; Karar, J., Maity, A., PI3K/AKT/mTOR pathway in angiogenesis (2011) Front. Mol. Neurosci., 4 (December (51)); Kasibhatla, M., Steinberg, P., Meyer, J., Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma (2007) Clin. Genitourin. Cancer, 5 (4), pp. 291-294; Kennecke, H., Berry, S., Wong, R., Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial (2012) Eur. J. Cancer, 48 (January (1)), pp. 37-45; Kiess, A.P., Wolchok, J.D., Barker, C.A., Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment (2015) Int. J. Radiat. Oncol. Biol. Phys., 92, pp. 368-375; Kim, D.Y., Park, W., Lim, D.H., Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma (2005) Cancer, 103, pp. 2419-2426; Kim, T.H., Kim, D.Y., Park, J.W., Thee-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable (2006) Am. J. Clin. Oncol., 29, pp. 568-575; Kleibeuker, E.A., Ten Hooven MA, Verheul HM et al. Combining radiotherapy with sunitinib: lessons (to be) learned (2015) Angiogenesis, 18 (October (4)), pp. 385-395; Knisely, J.P., Yu, J.B., Flanigan, J., Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival (2012) J. Neurosurg., 117, pp. 227-233; Kwon, E.D., Drake, C.G., Scher, H.I., CA184-043 Investigators, Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial (2014) Lancet Oncol., 15 (June (7)), pp. 700-712; Lai, A., Tran, A., Nghiemphu, P.L., Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme (2011) J Clin Oncol Off J Am Soc Clin Oncol, 29, pp. 142--1148; Landry, J.C., Feng, Y., Cohen, S.J., Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204 (2013) Cancer., 119 (April (8)), pp. 1521-1527; Leach, D., Krummel, M., Allison, J.P., Enhancement of anti-tumor immunity by CTLA4- blockade (1996) Science, 271, pp. 1734-1736; Lee, J.M., Mehta, U.N., Dsouza, L.H., Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report (2013) Melanoma Res., 23, pp. 175-178; Lee, S.M., Lewanski, C.R., Counsell, N., Randomized trial of erlotinib plus whole- brain radiotherapy for NSCLC patients with multiple brain metastases (2014) J. Natl. Cancer Inst., 106 (July (7)); Lefebvre, J.L., Pointreau, Y., Rolland, F., Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study (2013) J. Clin. Oncol., 31 (March (7)), pp. 853-859. , Epub 2013 Jan 22. Erratum in: J Clin Oncol. 2013 May 1;31(13):1702; Leibowitz-Amit, R., Joshua, A.M., Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions (2012) Curr. Oncol., 19, pp. S22-S31. , 18; Lledo, G., Huguet, F., Chibaudel, B., Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: the GERCOR phase II trial ERaFOX (2016) Eur. J. Cancer, 56 (March), pp. 115-121; Liccardi, G., Hartley, J.A., Hochhauser, D., Importance of EGFR/ERCC1 interaction following radiation-induced DNA damage (2014) Clin. Cancer Res., 20, pp. 3496-3506; Lilenbaum, R., Samuels, M., Wang, X., A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG) (2015) J. Thorac. Oncol., 10 (January (1)), pp. 143-147; Lin, S.H., Lin, Y., Price, J., DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab) [abstract] (2017) J. Clin. Oncol., 35. , (Abstr nr 3064); Liniker, E., Activity and safety of radiotherapy with Anti-PD-1 drug therapy in patients with metastatic melanoma (2016) OncoImmunol., 5 (9); Liu, L., Cao, Y., Chen, C., Zhang, X., Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 (2006) Cancer Res., 66 (24), pp. 11851-11858; Liu, Y., Poon, R.T., Li, Q., Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584 (2005) Cancer Res., 65 (May (9)), pp. 3691-3699; Lockhart, A.C., Reed, C.E., Decker, P.A., Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051) (2014) Ann. Oncol., 25 (May (5)), pp. 1039-1044; Locke, J.A., Dal Pra, A., Supiot, S., Synergistic action of image-guided radiotherapy and androgen deprivation therapy (2015) Nat. Rev. Urol., 12 (April (4)), pp. 193-204; Logothetis, C.J., Basch, E., Molina, Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial (2012) Lancet Oncol., 13 (12), pp. 1210-1217; Lorin, S., Codogno, P., Djavaheri-Mergny, M., Autophagy: a new concept in cancer research (2008) Bull. Cancer, 95 (January (1)), pp. 43-50; L{\'o}pez Estebaranz, J.L., Tratamiento del carcinoma basocelular invasivo o la v{\'i}a del erizo (2012) Piel, 27, pp. 425-428; Machiels, J.P., Sempoux, C., Scalliet, P., Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer (2007) Ann. Oncol., 18 (April (4)), pp. 738-744; Magrini, S.M., Buglione, M., Corv{\`o}, R., Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck Cancer: a randomized phase II trial (2016) J. Clin. Oncol., 34 (February (5)), pp. 427-435; Manegold, P.C., Paringer, C., Kulka, U., Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer (2008) Clin Cancer Res., 14 (3), pp. 892-900; Mao, Y., Huang, X., Shuang, Z., PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation (2018) Cancer Med., 7 (April (4)), pp. 1285-1296; Marur, S., Li, S., Cmelak, A.J., Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group (2016) J. Clin. Oncol., (December). , JCO2016683300; Martins, R.G., Parvathaneni, U., Bauman, J.E., Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial (2013) J. Clin. Oncol., 31 (April (11)), pp. 1415-1421; Martinez, E., Martinez, M., Rico, M., Feasibility, tolerability and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable NSCLC: a phase II trial (2016) Onco. Ther., 9 (March), pp. 1057-1066; Mart{\'i}nez-Fern{\'a}ndez, M.I., P{\'e}rez Gracia, J.L., Gil-Bazo, I., Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer (2016) Clin. Transl. Oncol., 18 (7), pp. 743-747; Mathew, M., Tam, M., Ott, P.A., Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery (2013) Melanoma Res., 23, pp. 191-195; Meattini, I., Cecchini, S., Muntoni, C., Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series (2014) Med. Oncol., 31 (April (4)), p. 891; Mehta, M.P., Wang, D., Wang, F., Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study (2015) J. Neurooncol., 122 (April (2)), pp. 409-417; Meng, E., Hanna, A., Samant, R.S., Shevde, L.A., The impact of hedgehog signaling pathway on DNA repair mechanisms in human cancer (2015) CancersBasel (Basel), 7, pp. 1333-1348; Mes{\'i}a, R., Henke, M., Fortin, A., Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial (2015) Lancet Oncol., 16 (February (2)), pp. 208-220; Michaelson, M.D., Hu, C., Pham, H.T., Phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery for non cystectomy candidates with muscle invasive bladder cancer (Trial NRG Oncology RTOG 0524) (2017) Int. J. Radiat. Oncol. Biol. Phys., 97 (April (5)), pp. 995-1001; Midgen, M.R., Guminski, A., Gutzmer, R., Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, doubleblind phase 2 trial (2015) Lancet Oncol., 16, pp. 716-728; Moasser, M.M., Krop, I.E., The evolving landscape of HER2 targeting in breast Cancer (2015) JAMA Oncol., 1. , 1154-116; Moilanen, A., Riikonen, R., Oksala, R., ODM-201—new generation antiandrogen with excellent antiandrogenic and antitumor activity in nonclinical models of CRPC (2013) Eur. J. Cancer, 49. , abstr 685; Motzer, R.J., Escudier, B., Oudard, S., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (2008) Lancet, 372 (August (9637)), pp. 449-456; Narayan, V., Vapiwala, N., Mick, R., Phase 1 trial of Everolimus and radiation therapy for salvage treatment of biochemical recurrence in prostate Cancer patients following prostatectomy (2017) Int. J. Radiat. Oncol. Biol. Phys., 97 (2), pp. 355-361; Narayana, A., Kelly, P., Golfinos, J., Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival (2009) J. Neurosurg., 110; Niraula, S., Chi, K., Joshua, A.M., Beyond castration-defining future directions in the hormonal treatment of prostate cancer (2012) Horm. Cancer, 3 (1-2), pp. 3-13; Nogu{\'e}, M., Salud, A., Vicente, P., Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study (2011) Oncologist., 16 (5), pp. 614-620; Nogueira-Rodrigues, A., Moralez, G., Grazziotin, R., Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer (2014) Cancer, 120 (April (8)), pp. 1187-1193; Nyati, M.K., Morgan, M.A., Feng, F.Y., Lawrence, T.S., Integration of EGFR inhibitors with radiochemotherapy (2006) Nat. Rev. Cancer, 6, pp. 876-885; Ostergaard, L., Tietze, A., Nielsen, T., The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis (2013) Cancer Res., , CAN-13-0964; Palumbo, S., Comincini, S., Autophagy and ionizing radiation in tumors: the “survive or not survive” dilemma (2013) J. Cell. Physiol., 228 (January (1)), pp. 1-8; Palumbo, I., Piattoni, S., Valentini, V., Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line (2014) Int. J. Colorectal Dis., 29 (1), pp. 31-41; Pan, S., Wu, X., Jiang, J., Discovery of NVP-LDE225, a potent and selective smoothened antagonist (2010) ACS Med. Chem. Lett., 1, pp. 130-134; Park, H.C., Seong, J., Han, K.H., Dose-response relationship in local radiotherapy for hepatocellular carcinoma (2002) Int. J. Radiat. Oncol. Biol. Phys., 54, pp. 150-155; Paris, F., Fuks, Z., Kang, A., Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice (2001) Science., 293 (July (5528)), pp. 293-297; Patel, K.R., Shoukat, S., Oliver, D.E., Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases (2017) Am. J. Clin. Oncol., 40 (October (5)), pp. 444-450; Perez, E.A., Suman, V.J., Davidson, N.E., Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer treatment Group N9831 adjuvant breast cancer trial (2008) J. Clin. Oncol., 26, pp. 1231-1238; Pesce, G.A., Klingbiel, D., Ribi, K., Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer research (SAKK 70/03) (2012) Eur. J. Cancer, 48 (February (3)), pp. 377-384; Petit, A.M., Rak, J., Hung, M.C., Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors (1997) Am. J. Pathol., 151, pp. 1523-1530; Pietras, R.J., Poen, J.C., Gallardo, D., Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene (1999) Cancer Res., 59 (6), pp. 1347-1355; Pollom, E.L., Bui, T.T., Chang, A.L., Concurrent vismodegib and radiotherapy for recurrent, advanced basal cell carcinoma (2015) JAMA Dermatol., 151, pp. 998-1001; Polivka, J., Jr, Polivka, J., Holubec, L., Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme (2017) Anticancer Res., 37 (January (1)), pp. 21-33; Postow, M.A., Callahan, M.K., Barker, C.A., Immunologic correlates of the abscopal effect in a patient with melanoma (2012) N. Engl. J. Med., 366 (10), pp. 925-931; Raleigh, D.R., Algazi, A., Arron, S.T., Induction Hedgehog pathway inhibition followed by combined-modality radiotherapy for basal cell carcinoma (2015) Br. J. Dermatol., 173, pp. 544-546; Ramella, S., Alberti, A.M., Cammilluzzi, E., Erlotinib and concurrent chemoradiation in pretreated NSCLC patients: radiobiological basis and clinical results (2013) Biomed Res. Int., 2013; Rathkopf, D.E., Antonarakis, E.S., Shore, N.D., Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate Cancer with and without prior abiraterone acetate and prednisone (2017) Clin. Cancer Res., (February); Reiss, K.A., Herman, J.M., Zahurak, M., A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis (2015) Clin. Cancer Res., 21 (January (1)), pp. 68-76; Romond, E.H., Perez, E.A., Bryant, J., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer (2005) N. Engl. J. Med., 353 (16), pp. 1673-1684; Ruhstaller, T., Pless, M., Dietrich, D., Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06) (2011) J. Clin. Oncol., 29 (February (6)), pp. 626-631; Ruhstaller, T., Thuss-Patience, P., Hayoz, S., Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08) (2018) Ann. Oncol., 29 (June (6)), pp. 1386-1393; Safran, H., Dipetrillo, T., Akerman, P., Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma (2007) Int J RadiatOncolBiol Phys, 67, pp. 405-409; Safran, H., Suntharalingam, M., Dipetrillo, T., Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity (2008) Int. J. Radiat. Oncol. Biol. Phys., 70 (February (2)), pp. 391-395; Salazar, R., Capdevila, J., Laquente, B., A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features (2015) BMC Cancer, 15 (February), p. 60; Sambade, M.J., Peters, E.C., Thomas, N.E., Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B- RAF with PLX-4032 (2011) Radiother Oncol., 98 (Mar. (3)), pp. 394-399; Sandomenico, C., Costanzo, R., Carillio, G., Bevacizumab in non small cell lung cancer: development, current status and issues (2012) Curr. Med. Chem., 19, pp. 961-971; Satoh, M.S., Poirier, G.G., Lindahl, T., NAD(+)-dependent repair of Damaged DNA by human cell extracts (1993) J. Biol. Chem., 268 (8), pp. 5480-5487; Scher, H.I., Fizazi, K., Saad, F., Increased survival with enzalutamide in prostate cancer after chemotherapy (2012) N. Engl. J. Med., 367 (13), pp. 1187-1197; Schueneman, A.J., Himmelfarb, E., Geng, L., SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models (2003) Cancer Res., 63, pp. 4009-4016; Schulze, B., Meissner, M., Ghanaati, S., Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck : first clinical experience with vismodegib for locally advanced disease (2016) Strahlenther. Onkol., 192, pp. 25-31; Seeley, A.R., De Los Santos, J.F., Conry, R.M., Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma (2015) Melanoma Res., 25, pp. 246-251; Sekulic, A., Migden, M.R., Lewis, K., ERIVANCE BCC investigators. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and s safety of vismodegib in advanced BCC (2015) J. Am. Acad. Dermatol., 72, pp. 1021-1026. , e8; Silk, A.W., Bassetti, M.F., West, B.T., Ipilimumab and radiation therapy for melanoma brain metastases (2013) Cancer Med., 2, pp. 899-906; Siu, L.L., Waldron, J.N., Chen, B.E., Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with Panitumumab in locoregionally advanced squamous cell head and neck carcinoma: a randomized clinical trial (2016) JAMA Oncol., (December); Slovin, S.F., Higano, C.S., Hamid, O., Ipilimumab alone or in combination with radiotherapy in metastatic castration resistant prostate cancer: results from an open- label, multicenter phase I/II study (2013) Ann. Oncol., 24, pp. 1813-1821; Smith, M.R., Antonarakis, E.S., Ryan, C.J., Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate Cancer cohort (2016) Eur. Urol., 70, pp. 963-970; Smith, M.R., Saad, F., Chowdhury S. Apalutamide treatment and metastasis-free survival in prostate Cancer (2018) N. Engl. J. Med., 378 (April (15)), pp. 1408-1418; Spigel, D.R., Bendell, J.C., McCleod, M., Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer (2012) Clin. Colorectal Cancer, 11 (March (1)), pp. 45-52; Staehler, M., Haseke, N., Stadler, T., Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer (2012) Urol. Oncol., 30 (May-June (3)), pp. 290-293; Staehler, M., Haseke, N., Nuhn, P., Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma (2011) BJU Int., 108 (September (5)), pp. 673-678; Steel, G.G., Peckham, M.J., Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity (1979) Int. J. Radiat. Oncol. Biol. Phys., 5 (1), pp. 85-91; Suntharalingam, M., Winter, K., Ilson, D., Effect of the addition of Cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal Cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial (2017) JAMA Oncol., 3 (November (11)), pp. 1520-1528; Tao, Y., Auperin, A., Sire, C., Improved outcome by adding concurrent chemotherapy to Cetuximab and radiotherapy for locally advanced head and neck carcinomas: results of the GORTEC 2007-01 phase III randomized trial (2018) J. Clin. Oncol., (June). , JCO2017762518; Thompson, R.H., Kuntz, S.M., Leibovich, B.C., Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up (2006) Cancer Res., 66, pp. 3381-3385; Tivol, E.A., Borriello, F., Schweitzer, A.N., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 (1995) Immunity, 3, pp. 541-547; Tombal, B., Borre, M., Rathenborg, P., Enzalutamide monotherapy in hormone- naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study (2014) Lancet Oncol., 15 (May (6)), pp. 592-600; Tomblyn, M.B., Goldman, B.H., Thomas, C.R., Jr, Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414) (2012) J. Thorac. Oncol., 7 (May (5)), pp. 906-912; Tong, C.C., Ko, E.C., Sung, M.W., Phase II trial of concurrent sunitinib and image- guided radiotherapy for oligometastases (2012) PLoS One, 7 (6); Topalian, S.L., Drake, C.G., Pardoll DM: targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity (2012) Curr. Opin. Immunol., 24, pp. 207-212; Triggiani, L., Alongi, F., Buglione, M., Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study (2017) Br. J. Cancer, 116 (12), pp. 1520-1525; Trino, E., Mantovani, C., Badellino, S., Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases (2017) Expert Rev. Anticancer Ther., 17 (April (4)), pp. 347-356; Trotti, A., Harris, J., Gillison, M., NRG-RTOG 1016: phase III trial comparing Radiation/Cetuximab to Radiation/Cisplatin in HPV-related Cancer of the oropharynx (2018) Int J Radiat Oncol Biol Phys. Supplement; Valabrega, G., Montemurro, F., Aglietta, M., Trastuzumab: mechanism of action, resistance and future perspectives in HER2- overexpressing breast cancer (2007) Ann. Oncol., 1, p. 17; Valentini, V., De Paoli, A., Gambacorta, M.A., Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092) (2008) Int J Radiat Oncol BiolPhys., 72 (November (3)), pp. 644-649; van den Heuvel, M.M., Uyterlinde, W., Vincent, A.D., Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating (2014) Radiother. Oncol., 110 (January (1)), pp. 126-131; Velenik, V., Ocvirk, J., Music, M., Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study (2011) Radiat. Oncol., 6 (August), p. 105; Verstraete, M., Debucquoy, A., Dekervel, J., Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial (2015) Br. J. Cancer, 112 (April (8)), pp. 1314-1325; Viloria-Petit, A., Crombet, T., Jothy, S., Acquired resistance to the antitumor effect of epidermal growth factor receptor blocking antibodies in vivo: a role for altered tumor angiogenesis (2001) Cancer Res., 61, pp. 5090-5101; Vivaldi, C., Buccianti, G., Musettini, F., TRUST: phase II trial of induction chemotherapy with FOLFOXIRI + Bevacizumab followed by chemo-radiotherapy + Bevacizumab and surgery in locally advanced rectal carcinoma (2016) Ann. Oncol., 27 (October (Suppl_6)); Walraven, I., van den Heuvel, M., van Diessen, J., Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab (2016) Radiother. Oncol., 118 (March (3)), pp. 442-446; Wang, Z., Zhu, X.X., Wu, X.H., Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer (2014) Am. J. Clin. Oncol., 37 (April (2)), pp. 148-153; Waterhouse, P., Penninger, J.M., Timms, E., Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 (1995) Science, 270, pp. 985-988; Weiner, L.M., Adams, G.P., New approaches to antibody therapy (2000) Oncogene, 19, pp. 6144-6151; Weis, S.M., Cheresh, D.A., Tumor angiogenesis: molecular pathways and therapeutic targets (2011) Nat. Med., 17 (11), pp. 1359-1370; Welsh, J.W., Komaki, R., Amini, A., Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer (2013) J. Clin. Oncol., 31 (March (7)), pp. 895-902; Wirsching, H.G., Tabatabai, G., Roelcke, U., Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial (2018) Ann. Oncol., 29 (June (6)), pp. 1423-1430; Wilhelm, S., Carter, C., Lynch, M., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer (2006) Nat. Rev. Drug Discov., 5 (10), pp. 835-844; Wellbrock, C., Karasarides, M., Marais, R., The RAF proteins take centre stage (2004) Nat. Rev. Mol. Cell Biol., 5, pp. 875-885; Willett, C.G., Duda, D.G., di Tomaso, E., Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study (2009) J. Clin. Oncol., 27 (June (18)), pp. 3020-3026; Yang, Q., Guan, K.-L., Expanding mTOR signaling (2007) Cell Res., 17, pp. 666-681; Yao, M., Woods, C., Lavertu, P., Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma (2016) Head Neck, 38 (April (Suppl 1)), pp. E1770-E1776; Zhang, H.P., Takayama, K., Su, B., Effect of sunitinib combined with ionizing radiation on endothelial cells (2011) J. Radiat. Res., 52, pp. 1-8; Zhang, Y., Wang, L., Li, Y., Protein expression of programmed death 1 ligand1 and ligand2 independently predict poor prognosis in surgically resected lung adenocarcinoma (2014) Onco. Ther., 7, pp. 567-573; Zhao, C., Lin, L., Liu, J., A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma (2016) Oncotarget., 7 (August (35)), pp. 57310-57316; Zhuang, H., Yuan, Z., Wang, J., Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma (2013) Drug Des. Devel. Ther., 7 (October), pp. 1179-1186; Zwolak, P., Jasinski, P., Terai, K., Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone (2008) Eur. J. Cancer, 44, pp. 2506-2517",

year = "2019",

doi = "10.1016/j.critrevonc.2018.11.005",

language = "English",

volume = "134",

pages = "87--103",

journal = "Crit. Rev. Oncol. Hematol.",

issn = "1879-0461",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy

T2 - Critical Reviews in Oncology/Hematology

AU - Arcangeli, S.

AU - Jereczek-Fossa, B.A.

AU - Alongi, F.

AU - Aristei, C.

AU - Becherini, C.

AU - Belgioia, L.

AU - Buglione, M.

AU - Caravatta, L.

AU - D'Angelillo, R.M.

AU - Filippi, A.R.

AU - Fiore, M.

AU - Genovesi, D.

AU - Greco, C.

AU - Livi, L.

AU - Magrini, S.M.

AU - Marvaso, G.

AU - Mazzola, R.

AU - Meattini, I.

AU - Merlotti, A.

AU - Palumbo, I.

AU - Pergolizzi, S.

AU - Ramella, S.

AU - Ricardi, U.

AU - Russi, E.

AU - Trovò, M.

AU - Sindoni, A.

AU - Valentini, V.

AU - Corvò, R.

N1 - Export Date: 25 February 2020 CODEN: CCRHE Correspondence Address: Arcangeli, S.; Department of Radiation Oncology, Policlinico S. Gerardo and University of Milan “Bicocca”, Via Pergolesi 33, Monza (MB) – Italy, Italy; email: stefano.arcangeli@yahoo.it Chemicals/CAS: abiraterone, 154229-19-3; anastrozole, 120511-73-1; apalutamide, 956104-40-8; bevacizumab, 216974-75-3, 1438851-35-4; capecitabine, 154361-50-9; cetuximab, 205923-56-4; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; docetaxel, 114977-28-5; enzalutamide, 915087-33-1; erlotinib, 183319-69-9, 183321-74-6; everolimus, 159351-69-6; exemestane, 107868-30-4; gemcitabine, 103882-84-4; imatinib, 152459-95-5, 220127-57-1; letrozole, 112809-51-5; oxaliplatin, 61825-94-3; paclitaxel, 33069-62-4; panitumumab, 339177-26-3; sonidegib, 956697-53-3, 1218778-77-8; sorafenib, 284461-73-0; sunitinib, 341031-54-7, 557795-19-4; temozolomide, 85622-93-1; trastuzumab, 180288-69-1, 1446410-98-5; veliparib, 912444-00-9; vemurafenib, 918504-65-1; vismodegib, 879085-55-9; Radiation-Sensitizing Agents References: Ahmed, K.A., Stallworth, D.G., Kim, Y., Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy (2016) Ann. Oncol., 27, pp. 434-441; Amici, J.M., Beylot-Barry, M., Locally advanced basal-cell carcinoma: combined alternative treatments beyond surgery (2015) Ann. Chir. Plast. Esthet., 60, pp. 321-325; Ang, K.K., Zhang, Q., Rosenthal, D.I., Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522 (2014) J. Clin. Oncol., 32 (September (27)), pp. 2940-2950; Antonia, S.J., Villegas, A., Daniel, D., Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer (2017) N. Engl. J. Med., 377, pp. 1919-1929; Antonia, S.J., Villegas, A., Daniel, D., Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC (2018) N. Engl. J. Med.; Argiris, A., Heron, D.E., Smith, R.P., Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer (2010) J. Clin. Oncol., 28 (December (36)), pp. 5294-5300; Avallone, A., Pecori, B., Bianco, F., Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: results of the BRANCH trial (2015) Oncotarget., 6 (October (30)), pp. 30394-30407; Azria, D., Larbouret, C., Robert, B., Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials (2003) Bull. Cancer, 90, pp. S202-S212; Badache, A., Hynes, N.E., A new therapeutic antibody masks ErbB2 to its partners (2004) Cancer Cell, 5, pp. 299-301. , 27; Balana, C., De Las Penas, R., Sepúlveda, J.M., A multicenter randomized study comparing temozolomide (TMZ) versus TMZ-plus-bevacizumab (BEV) before standard treatment in unresectable glioblastoma (GBM) patients (p): the GENOM 009 study by the GEINO group (2014) J. Clin. Oncol., 32 (5s). , suppl; abstr 2028; Baroudjian, B., Boussemart, L., Routier, E., Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer? (2014) Eur. J. Dermatol., 24, pp. 265-267; Bartek, J., Mistrik, M., Bartkova, J., Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer (2013) Cancer Discov., 3, pp. 1222-1224; Basset-Seguin, N., Hauschild, A., Grob, J., Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial (2015) Lancet Oncol., 16, pp. 729-736; Baumann, M., Krause, M., Dikomey, E., EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms (2007) Radiother. Oncol., 83, pp. 238-248; Beer, T.M., Armstrong, A.J., Rathkopf, D.E., Enzalutamide in metastatic prostate cancer before chemotherapy (2014) N. Engl. J. Med., 371, pp. 424-433; Beaver, J.A., Park, B.H., The BOLERO-2 trial: the addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer (2012) Future Oncol., 8 (June (6)), pp. 651-657; Belkacémi, Y., Gligorov, J., Ozsahin, M., Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study (2008) Ann. Oncol., 19, pp. 1110-1116; Blumenschein, G.R., Jr, Paulus, R., Curran, W.J., Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324 (2011) J. Clin. Oncol., 29 (June (17)), pp. 2312-2318; Blaszkowsky, L.S., Ryan, D.P., Szymonifka, J., Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer (2014) Ann. Oncol., 25 (January (1)), pp. 121-126; Block, A.M., Alite, F., Diaz, A.Z., Combination trimodality therapy using vismodegib for basal cell carcinoma of the face (2015) Case Rep. Oncol. Med., 2015; Bonner, J.A., Harari, P.M., Giralt, J., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck (2006) N. Engl. J. Med., 354 (February (6)), pp. 567-578; Bradley, J.D., Paulus, R., Komaki, R., Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study (2015) Lancet Oncol., 16 (February (2)), pp. 187-199; Buglione, M., Maddalo, M., Corvò, R., Subgroup analysis according to human papillomavirus status and tumor site of a randomized phase II trial comparing cetuximab and cisplatin combined with radiation therapy for locally advanced head and neck Cancer (2017) Int. J. Radiat. Oncol. Biol. Phys., 97 (March (3)), pp. 462-472; Caffo, O., Maines, F., Donner, D., Impact of enzalutamide administration on primary prostate cancer volume: a metabolic evaluation by choline positron emission tomography in castration-resistant prostate cancer patients (2014) Clin. Genitourin. Cancer, 12 (October (5)), pp. 312-316; Carmeliet, P., Jain, R.K., Angiogenesis in cancer and other diseases (2000) Nature., 407 (September (6801)), pp. 249-257; Ceolin Foletto, M., Haas, S.E., Cutaneous melanoma: new advances in treatment (2014) An. Bras. Dermatol., 89 (March-April (2)), pp. 301-310; Crane, C.H., Eng, C., Feig, B.W., Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer (2010) Int. J. Radiat. Oncol. Biol. Phys., 76 (March (3)), pp. 824-830; Crosby, T., Hurt, C.N., Falk, S., Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial (2013) Lancet Oncol., 14 (June (7)), pp. 627-637; Chalmers, A., PARP-1 PARP-2, and the cellular response to low doses of ionizing radiation (2004) Int. J. Radiat. Oncol. Biol. Phys., 58 (2), pp. 410-419; Chandra, R.A., Wilhite, T.J., Balboni, T.A., A systematic evaluation of abscopal responses following RT in metastatic melanoma patients treated with ipilimumab (2015) Oncoimmunology, 4 (11); Chang, A.L., Solomon, J.A., Hainsworth, J.D., Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib (2014) J. Am. Acad. Dermatol., 70, pp. 60-69; Chen, D.J., Nirodi, C.S., The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage (2007) Clin. Cancer Res., 13, pp. 6555-6560; Chen, S.W., Lin, L.C., Kuo, Y.C., Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma (2014) Int. J. Radiat. Oncol. Biol. Phys., 88 (5), pp. 1041-1047; Cheng, A.L., Kang, Y.K., Chen, Z., Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial (2009) Lancet Oncol., 10 (1), pp. 25-34; Chinnaiyan, P., Huang, S., Vallabhaneni, G., Mechanisms ofenhanced radiation response following epidermal growth factorreceptor signaling inhibition by erlotinib (Tarceva) (2005) Cancer Res., 65 (8), pp. 3328-3335; Chinnaiyan, P., Won, M., Wen, P.Y., A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913 (2018) Neuro Oncol., 20 (April (5)), pp. 666-673; Chinot, O.L., Wick, W., Mason, W., Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma (2014) N. Engl. J. Med., 370, pp. 709-722; Cho, E., Mostaghel, E.A., Russell, K.J., External beam radiation therapy and abiraterone in men with localized prostate cancer: safety and effect on tissue androgens (2015) Int. J. Radiat. Oncol. Biol. Phys., 92 (June (2)), pp. 236-243; Cuneo, K.C., Geng, L., Fu, A., SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation (2008) Int. J. Radiat. Oncol. Biol. Phys., 71, pp. 873-879; de Melo, A.C., Grazziotin-Reisner, R., Erlich, F., A phase I study of mTOR inhibitor everolimus in association with cisplatin and radiotherapy for the treatment of locally advanced cervix cancer: PHOENIX I (2016) Cancer Chemother. Pharmacol., 78 (1), pp. 101-109; Dellas, K., Höhler, T., Reese, T., Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer (2013) Radiat. Oncol., 8 (April), p. 90; Detti, B., D'Angelillo, R.M., Ingrosso, G., Combining abiraterone and radiotherapy in prostate Cancer patients who progressed during abiraterone therapy (2017) Anticancer Res., 37 (July (7)), pp. 3717-3722; Deutsch, E., Le Péchoux, C., Faivre, L., Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer (2015) Ann. Oncol., 26, pp. 1223-1229; Dipetrillo, T., Pricolo, V., Lagares-Garcia, J., Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer (2012) Int. J. Radiat. Oncol. Biol. Phys., 82 (January (1)), pp. 124-129; Dong, H., Strome, S.E., Salomao, D.R., Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion (2002) Nat. Med., 8, pp. 793-800; Dwedney, A., Cunningham, D., Tabernero, J., Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C) (2012) J. Clin. Oncol., 30 (May (14)), pp. 1620-1627; Escudier, B., Eisen, T., Stadler, W.M., Sorafenib in advanced clear-cell renal-cell carcinoma (2007) N. Engl. J. Med., 356 (2), pp. 125-134; Ferrara, N., VEGF and the quest for tumour angiogenesis factors (2002) Nat. Rev. Cancer, 2 (10), pp. 795-803; Ferrarelli, L.K., Hormones in repair and resistance (2013) Sci. Signal., 6, p. 304. , pp.ec 293; Filippi, A.R., Fava, P., Badellino, S., Astrua, C., Ricardi, U., Quaglino, P., Radiotherapy and immune checkpoints inhibitors for advanced melanoma (2016) Radiother. Oncol., 120 (July (1)), pp. 1-12; Folkman, J., Tumor angiogenesis: therapeutic implications (1971) N. Engl. J. Med., (21), pp. 1182-1186; Fornaro, L., Caparello, C., Vivaldi, C., Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review (2014) World J. Gastroenterol., 20 (May (20)), pp. 6081-6091; Fizazi, K., Massard, C., James, N.D., ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: preclinical and phase I data (2013) Proc Am Soc Clin Oncol, 31. , abstr 65. 19; Fu, P., He, Y.S., Huang, Q., Bevacizumab treatment for newly diagnosed glioblastoma: systematic review and meta-analysis of clinical trials (2016) Mol. Clin. Oncol., 4 (May (5)), pp. 833-838; Fury, M.G., Lee, N.Y., Sherman, E., A phase I study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer (2013) Int. J. Radiat. Oncol. Biol. Phys., 87 (November (3)), pp. 479-486; Gani, C., Coackley, C., Kumareswaran, R., In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: an exploration of the therapeutic ratio (2015) Radiother. Oncol 2015, 116 (September (3)), pp. 486-494; Garcia-Barros, M., Paris, F., Cordon-Cardo, C., Tumor response to radiotherapy regulated by endothelial cell apoptosis (2003) Science., 300 (May (5622)), pp. 1155-1159; Garcia-Barros, M., Moeller, B.J., Cao, Y., Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules (2004) Cancer Cell, 5 (May (5)), pp. 429-441; Gasparini, G., Torino, F., Ueno, T., A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer (2012) Angiogenesis., 15 (March (1)), pp. 141-150; Geoffrois, L., Martin, L., De Raucourt, D., Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas. Results of the GORTEC-02 phase III randomized trial (2018) J. Clin. Oncol., (July); Ghashghaei, M., Muanza, T., Paliouras, M., Niazi, T., Effect of enzalutamide on sensitivity in prostate cancer cells to radiation by inhibition of DNA double strand break repair (2017) J. Clin. Oncol., 35 (6_suppl). , 208-208; Gilbert, M.R., Dignam, J.J., Armstrong, T.S., A randomized trial of bevacizumab for newly diagnosed glioblastoma (2014) N. Engl. J. Med., 370, pp. 699-708; Giralt, J., Trigo, J., Nuyts, S., Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous cell carcinoma of the head and neck (CONCERT-2): a randomized controlled, open label phase 2 trial (2015) Lancet Oncol., 16 (February (2)), pp. 221-232; Goding, S.R., Wilson, K.A., Xie, Y., Restoring immune function of Tumor specific CD4 ﬂ T cells during recurrence of melanoma (2013) J. Immunol., 190, pp. 4899-4909; Golden, E.B., Demaria, S., Schiff, P.B., An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer (2013) Cancer Immunol. Res., 1, pp. 365-372; Gorski, D.H., Beckett, M.A., Jaskowiak, N.T., Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation (1999) Cancer Res., 59 (14), pp. 3374-3378; Govindan, R., Bogart, J., Stinchcombe, T., Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: cancer and Leukemia Group B trial 30407 (2011) J. Clin. Oncol., 29 (August (23)), pp. 3120-3125; Grimaldi, A.M., Simeone, E., Giannarelli, D., Abscopal effects of RT on advanced melanoma patients who progressed after ipilimumab immunotherapy (2014) Oncoimmunology, p. e28780. , 1-8; Gullick, W.J., Downward, J., Parker, P.J., The structure and function of the epidermal growth factor receptor studied by using antisynthetic peptide antibodies (1985) Proc. R. Soc. Lond., B, Biol. Sci., 226, pp. 127-134; Hainsworth, J.D., Spigel, D.R., Greco, F.A., Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium (2011) Cancer J., 17 (September-October (5)), pp. 267-272; Halyard, M.Y., Pisansky, T.M., Dueck, A.C., Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831 (2009) J. Clin. Oncol., 27, pp. 2638-2644; Hammel, P., Huguet, F., van Laethem, J.L., Effect of Chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic Cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial (2016) JAMA., 315 (May (17)), pp. 1844-1853; Hauschild, A., Grob, J.J., Demidov, L.V., Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial (2012) Lancet., 380 (July (9839)), pp. 358-365; Helbling, D., Bodoky, G., Gautschi, O., Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07 (2013) Ann. Oncol., 24 (March (3)), pp. 718-725; Herchenhorn, D., Dias, F.L., Viegas, C.M., Phase I/II study of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (2010) Int. J. Radiat. Oncol. Biol. Phys., 78 (November (3)), pp. 696-702; Herman, J.M., Fan, K.Y., Wild, A.T., Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer (2013) Int. J. Radiat. Oncol. Biol. Phys., 86 (July (4)), pp. 678-685; Hiniker, S.M., Chen, D.S., Reddy, S., A systemic complete response of metastatic melanoma to local radiation and immunotherapy (2012) Transl. Oncol., 5 (6), pp. 404-407; Hofheinz, R.D., Horisberger, K., Woernle, C., Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer (2006) Int. J. Radiat. Oncol. Biol. Phys., 66 (December (5)), pp. 1384-1390; Horton, J.K., Halle, J., Ferraro, M., Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trial (2010) Int. J. Radiat. Oncol. Biol. Phys., 76 (March (4)), pp. 998-1004; Huang, S.M., Harari, P.M., Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis (2000) Clin. Cancer Res., 6, pp. 2166-2174; Clifford, A., Hudis, M.D., Trastuzumab—mechanism of action and use in clinical practice (2007) NEJM, 357 (1), pp. 39-51; Iyengar, P., Kavanagh, B.D., Wardak, Z., Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer (2014) J. Clin. Oncol., 32 (December (34)), pp. 3824-3830; Jacobsen, A.A., Strasswimmer, J., Spontaneous resolution of advanced basal cell carcinoma after short-pulse treatment with hedgehog pathway inhibitor (2016) JAAD Case Rep., 30 (2), pp. 360-361; Kao, J., Packer, S., Vu, H.L., Phase 1 study of concurrent sunitinib and image- guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response (2009) Cancer, 115 (August (15)), pp. 3571-3580; Kao, J., Chen, C.T., Tong, C.C., Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases: final report of a prospective clinical trial (2014) Target. Oncol., 9 (June (2)), pp. 145-153; Karar, J., Maity, A., PI3K/AKT/mTOR pathway in angiogenesis (2011) Front. Mol. Neurosci., 4 (December (51)); Kasibhatla, M., Steinberg, P., Meyer, J., Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma (2007) Clin. Genitourin. Cancer, 5 (4), pp. 291-294; Kennecke, H., Berry, S., Wong, R., Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial (2012) Eur. J. Cancer, 48 (January (1)), pp. 37-45; Kiess, A.P., Wolchok, J.D., Barker, C.A., Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment (2015) Int. J. Radiat. Oncol. Biol. Phys., 92, pp. 368-375; Kim, D.Y., Park, W., Lim, D.H., Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma (2005) Cancer, 103, pp. 2419-2426; Kim, T.H., Kim, D.Y., Park, J.W., Thee-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable (2006) Am. J. Clin. Oncol., 29, pp. 568-575; Kleibeuker, E.A., Ten Hooven MA, Verheul HM et al. Combining radiotherapy with sunitinib: lessons (to be) learned (2015) Angiogenesis, 18 (October (4)), pp. 385-395; Knisely, J.P., Yu, J.B., Flanigan, J., Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival (2012) J. Neurosurg., 117, pp. 227-233; Kwon, E.D., Drake, C.G., Scher, H.I., CA184-043 Investigators, Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial (2014) Lancet Oncol., 15 (June (7)), pp. 700-712; Lai, A., Tran, A., Nghiemphu, P.L., Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme (2011) J Clin Oncol Off J Am Soc Clin Oncol, 29, pp. 142--1148; Landry, J.C., Feng, Y., Cohen, S.J., Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204 (2013) Cancer., 119 (April (8)), pp. 1521-1527; Leach, D., Krummel, M., Allison, J.P., Enhancement of anti-tumor immunity by CTLA4- blockade (1996) Science, 271, pp. 1734-1736; Lee, J.M., Mehta, U.N., Dsouza, L.H., Long-term stabilization of leptomeningeal disease with whole-brain radiation therapy in a patient with metastatic melanoma treated with vemurafenib: a case report (2013) Melanoma Res., 23, pp. 175-178; Lee, S.M., Lewanski, C.R., Counsell, N., Randomized trial of erlotinib plus whole- brain radiotherapy for NSCLC patients with multiple brain metastases (2014) J. Natl. Cancer Inst., 106 (July (7)); Lefebvre, J.L., Pointreau, Y., Rolland, F., Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study (2013) J. Clin. Oncol., 31 (March (7)), pp. 853-859. , Epub 2013 Jan 22. Erratum in: J Clin Oncol. 2013 May 1;31(13):1702; Leibowitz-Amit, R., Joshua, A.M., Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions (2012) Curr. Oncol., 19, pp. S22-S31. , 18; Lledo, G., Huguet, F., Chibaudel, B., Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: the GERCOR phase II trial ERaFOX (2016) Eur. J. Cancer, 56 (March), pp. 115-121; Liccardi, G., Hartley, J.A., Hochhauser, D., Importance of EGFR/ERCC1 interaction following radiation-induced DNA damage (2014) Clin. Cancer Res., 20, pp. 3496-3506; Lilenbaum, R., Samuels, M., Wang, X., A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG) (2015) J. Thorac. Oncol., 10 (January (1)), pp. 143-147; Lin, S.H., Lin, Y., Price, J., DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab) [abstract] (2017) J. Clin. Oncol., 35. , (Abstr nr 3064); Liniker, E., Activity and safety of radiotherapy with Anti-PD-1 drug therapy in patients with metastatic melanoma (2016) OncoImmunol., 5 (9); Liu, L., Cao, Y., Chen, C., Zhang, X., Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 (2006) Cancer Res., 66 (24), pp. 11851-11858; Liu, Y., Poon, R.T., Li, Q., Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584 (2005) Cancer Res., 65 (May (9)), pp. 3691-3699; Lockhart, A.C., Reed, C.E., Decker, P.A., Phase II study of neoadjuvant therapy with docetaxel, cisplatin, panitumumab, and radiation therapy followed by surgery in patients with locally advanced adenocarcinoma of the distal esophagus (ACOSOG Z4051) (2014) Ann. Oncol., 25 (May (5)), pp. 1039-1044; Locke, J.A., Dal Pra, A., Supiot, S., Synergistic action of image-guided radiotherapy and androgen deprivation therapy (2015) Nat. Rev. Urol., 12 (April (4)), pp. 193-204; Logothetis, C.J., Basch, E., Molina, Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial (2012) Lancet Oncol., 13 (12), pp. 1210-1217; Lorin, S., Codogno, P., Djavaheri-Mergny, M., Autophagy: a new concept in cancer research (2008) Bull. Cancer, 95 (January (1)), pp. 43-50; López Estebaranz, J.L., Tratamiento del carcinoma basocelular invasivo o la vía del erizo (2012) Piel, 27, pp. 425-428; Machiels, J.P., Sempoux, C., Scalliet, P., Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer (2007) Ann. Oncol., 18 (April (4)), pp. 738-744; Magrini, S.M., Buglione, M., Corvò, R., Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck Cancer: a randomized phase II trial (2016) J. Clin. Oncol., 34 (February (5)), pp. 427-435; Manegold, P.C., Paringer, C., Kulka, U., Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer (2008) Clin Cancer Res., 14 (3), pp. 892-900; Mao, Y., Huang, X., Shuang, Z., PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation (2018) Cancer Med., 7 (April (4)), pp. 1285-1296; Marur, S., Li, S., Cmelak, A.J., Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group (2016) J. Clin. Oncol., (December). , JCO2016683300; Martins, R.G., Parvathaneni, U., Bauman, J.E., Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial (2013) J. Clin. Oncol., 31 (April (11)), pp. 1415-1421; Martinez, E., Martinez, M., Rico, M., Feasibility, tolerability and efficacy of the concurrent addition of erlotinib to thoracic radiotherapy in locally advanced unresectable NSCLC: a phase II trial (2016) Onco. Ther., 9 (March), pp. 1057-1066; Martínez-Fernández, M.I., Pérez Gracia, J.L., Gil-Bazo, I., Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer (2016) Clin. Transl. Oncol., 18 (7), pp. 743-747; Mathew, M., Tam, M., Ott, P.A., Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery (2013) Melanoma Res., 23, pp. 191-195; Meattini, I., Cecchini, S., Muntoni, C., Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series (2014) Med. Oncol., 31 (April (4)), p. 891; Mehta, M.P., Wang, D., Wang, F., Veliparib in combination with whole brain radiation therapy in patients with brain metastases: results of a phase 1 study (2015) J. Neurooncol., 122 (April (2)), pp. 409-417; Meng, E., Hanna, A., Samant, R.S., Shevde, L.A., The impact of hedgehog signaling pathway on DNA repair mechanisms in human cancer (2015) CancersBasel (Basel), 7, pp. 1333-1348; Mesía, R., Henke, M., Fortin, A., Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial (2015) Lancet Oncol., 16 (February (2)), pp. 208-220; Michaelson, M.D., Hu, C., Pham, H.T., Phase I/II trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation following transurethral surgery for non cystectomy candidates with muscle invasive bladder cancer (Trial NRG Oncology RTOG 0524) (2017) Int. J. Radiat. Oncol. Biol. Phys., 97 (April (5)), pp. 995-1001; Midgen, M.R., Guminski, A., Gutzmer, R., Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, doubleblind phase 2 trial (2015) Lancet Oncol., 16, pp. 716-728; Moasser, M.M., Krop, I.E., The evolving landscape of HER2 targeting in breast Cancer (2015) JAMA Oncol., 1. , 1154-116; Moilanen, A., Riikonen, R., Oksala, R., ODM-201—new generation antiandrogen with excellent antiandrogenic and antitumor activity in nonclinical models of CRPC (2013) Eur. J. Cancer, 49. , abstr 685; Motzer, R.J., Escudier, B., Oudard, S., Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial (2008) Lancet, 372 (August (9637)), pp. 449-456; Narayan, V., Vapiwala, N., Mick, R., Phase 1 trial of Everolimus and radiation therapy for salvage treatment of biochemical recurrence in prostate Cancer patients following prostatectomy (2017) Int. J. Radiat. Oncol. Biol. Phys., 97 (2), pp. 355-361; Narayana, A., Kelly, P., Golfinos, J., Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival (2009) J. Neurosurg., 110; Niraula, S., Chi, K., Joshua, A.M., Beyond castration-defining future directions in the hormonal treatment of prostate cancer (2012) Horm. Cancer, 3 (1-2), pp. 3-13; Nogué, M., Salud, A., Vicente, P., Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study (2011) Oncologist., 16 (5), pp. 614-620; Nogueira-Rodrigues, A., Moralez, G., Grazziotin, R., Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer (2014) Cancer, 120 (April (8)), pp. 1187-1193; Nyati, M.K., Morgan, M.A., Feng, F.Y., Lawrence, T.S., Integration of EGFR inhibitors with radiochemotherapy (2006) Nat. Rev. Cancer, 6, pp. 876-885; Ostergaard, L., Tietze, A., Nielsen, T., The relationship between tumor blood flow, angiogenesis, tumor hypoxia, and aerobic glycolysis (2013) Cancer Res., , CAN-13-0964; Palumbo, S., Comincini, S., Autophagy and ionizing radiation in tumors: the “survive or not survive” dilemma (2013) J. Cell. Physiol., 228 (January (1)), pp. 1-8; Palumbo, I., Piattoni, S., Valentini, V., Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line (2014) Int. J. Colorectal Dis., 29 (1), pp. 31-41; Pan, S., Wu, X., Jiang, J., Discovery of NVP-LDE225, a potent and selective smoothened antagonist (2010) ACS Med. Chem. Lett., 1, pp. 130-134; Park, H.C., Seong, J., Han, K.H., Dose-response relationship in local radiotherapy for hepatocellular carcinoma (2002) Int. J. Radiat. Oncol. Biol. Phys., 54, pp. 150-155; Paris, F., Fuks, Z., Kang, A., Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice (2001) Science., 293 (July (5528)), pp. 293-297; Patel, K.R., Shoukat, S., Oliver, D.E., Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases (2017) Am. J. Clin. Oncol., 40 (October (5)), pp. 444-450; Perez, E.A., Suman, V.J., Davidson, N.E., Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer treatment Group N9831 adjuvant breast cancer trial (2008) J. Clin. Oncol., 26, pp. 1231-1238; Pesce, G.A., Klingbiel, D., Ribi, K., Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer research (SAKK 70/03) (2012) Eur. J. Cancer, 48 (February (3)), pp. 377-384; Petit, A.M., Rak, J., Hung, M.C., Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors (1997) Am. J. Pathol., 151, pp. 1523-1530; Pietras, R.J., Poen, J.C., Gallardo, D., Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene (1999) Cancer Res., 59 (6), pp. 1347-1355; Pollom, E.L., Bui, T.T., Chang, A.L., Concurrent vismodegib and radiotherapy for recurrent, advanced basal cell carcinoma (2015) JAMA Dermatol., 151, pp. 998-1001; Polivka, J., Jr, Polivka, J., Holubec, L., Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme (2017) Anticancer Res., 37 (January (1)), pp. 21-33; Postow, M.A., Callahan, M.K., Barker, C.A., Immunologic correlates of the abscopal effect in a patient with melanoma (2012) N. Engl. J. Med., 366 (10), pp. 925-931; Raleigh, D.R., Algazi, A., Arron, S.T., Induction Hedgehog pathway inhibition followed by combined-modality radiotherapy for basal cell carcinoma (2015) Br. J. Dermatol., 173, pp. 544-546; Ramella, S., Alberti, A.M., Cammilluzzi, E., Erlotinib and concurrent chemoradiation in pretreated NSCLC patients: radiobiological basis and clinical results (2013) Biomed Res. Int., 2013; Rathkopf, D.E., Antonarakis, E.S., Shore, N.D., Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate Cancer with and without prior abiraterone acetate and prednisone (2017) Clin. Cancer Res., (February); Reiss, K.A., Herman, J.M., Zahurak, M., A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis (2015) Clin. Cancer Res., 21 (January (1)), pp. 68-76; Romond, E.H., Perez, E.A., Bryant, J., Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer (2005) N. Engl. J. Med., 353 (16), pp. 1673-1684; Ruhstaller, T., Pless, M., Dietrich, D., Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06) (2011) J. Clin. Oncol., 29 (February (6)), pp. 626-631; Ruhstaller, T., Thuss-Patience, P., Hayoz, S., Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08) (2018) Ann. Oncol., 29 (June (6)), pp. 1386-1393; Safran, H., Dipetrillo, T., Akerman, P., Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma (2007) Int J RadiatOncolBiol Phys, 67, pp. 405-409; Safran, H., Suntharalingam, M., Dipetrillo, T., Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity (2008) Int. J. Radiat. Oncol. Biol. Phys., 70 (February (2)), pp. 391-395; Salazar, R., Capdevila, J., Laquente, B., A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features (2015) BMC Cancer, 15 (February), p. 60; Sambade, M.J., Peters, E.C., Thomas, N.E., Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B- RAF with PLX-4032 (2011) Radiother Oncol., 98 (Mar. (3)), pp. 394-399; Sandomenico, C., Costanzo, R., Carillio, G., Bevacizumab in non small cell lung cancer: development, current status and issues (2012) Curr. Med. Chem., 19, pp. 961-971; Satoh, M.S., Poirier, G.G., Lindahl, T., NAD(+)-dependent repair of Damaged DNA by human cell extracts (1993) J. Biol. Chem., 268 (8), pp. 5480-5487; Scher, H.I., Fizazi, K., Saad, F., Increased survival with enzalutamide in prostate cancer after chemotherapy (2012) N. Engl. J. Med., 367 (13), pp. 1187-1197; Schueneman, A.J., Himmelfarb, E., Geng, L., SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models (2003) Cancer Res., 63, pp. 4009-4016; Schulze, B., Meissner, M., Ghanaati, S., Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck : first clinical experience with vismodegib for locally advanced disease (2016) Strahlenther. Onkol., 192, pp. 25-31; Seeley, A.R., De Los Santos, J.F., Conry, R.M., Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma (2015) Melanoma Res., 25, pp. 246-251; Sekulic, A., Migden, M.R., Lewis, K., ERIVANCE BCC investigators. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and s safety of vismodegib in advanced BCC (2015) J. Am. Acad. Dermatol., 72, pp. 1021-1026. , e8; Silk, A.W., Bassetti, M.F., West, B.T., Ipilimumab and radiation therapy for melanoma brain metastases (2013) Cancer Med., 2, pp. 899-906; Siu, L.L., Waldron, J.N., Chen, B.E., Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with Panitumumab in locoregionally advanced squamous cell head and neck carcinoma: a randomized clinical trial (2016) JAMA Oncol., (December); Slovin, S.F., Higano, C.S., Hamid, O., Ipilimumab alone or in combination with radiotherapy in metastatic castration resistant prostate cancer: results from an open- label, multicenter phase I/II study (2013) Ann. Oncol., 24, pp. 1813-1821; Smith, M.R., Antonarakis, E.S., Ryan, C.J., Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate Cancer cohort (2016) Eur. Urol., 70, pp. 963-970; Smith, M.R., Saad, F., Chowdhury S. Apalutamide treatment and metastasis-free survival in prostate Cancer (2018) N. Engl. J. Med., 378 (April (15)), pp. 1408-1418; Spigel, D.R., Bendell, J.C., McCleod, M., Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer (2012) Clin. Colorectal Cancer, 11 (March (1)), pp. 45-52; Staehler, M., Haseke, N., Stadler, T., Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer (2012) Urol. Oncol., 30 (May-June (3)), pp. 290-293; Staehler, M., Haseke, N., Nuhn, P., Simultaneous anti-angiogenic therapy and single-fraction radiosurgery in clinically relevant metastases from renal cell carcinoma (2011) BJU Int., 108 (September (5)), pp. 673-678; Steel, G.G., Peckham, M.J., Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity (1979) Int. J. Radiat. Oncol. Biol. Phys., 5 (1), pp. 85-91; Suntharalingam, M., Winter, K., Ilson, D., Effect of the addition of Cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal Cancer: the NRG oncology RTOG 0436 phase 3 randomized clinical trial (2017) JAMA Oncol., 3 (November (11)), pp. 1520-1528; Tao, Y., Auperin, A., Sire, C., Improved outcome by adding concurrent chemotherapy to Cetuximab and radiotherapy for locally advanced head and neck carcinomas: results of the GORTEC 2007-01 phase III randomized trial (2018) J. Clin. Oncol., (June). , JCO2017762518; Thompson, R.H., Kuntz, S.M., Leibovich, B.C., Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up (2006) Cancer Res., 66, pp. 3381-3385; Tivol, E.A., Borriello, F., Schweitzer, A.N., Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4 (1995) Immunity, 3, pp. 541-547; Tombal, B., Borre, M., Rathenborg, P., Enzalutamide monotherapy in hormone- naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study (2014) Lancet Oncol., 15 (May (6)), pp. 592-600; Tomblyn, M.B., Goldman, B.H., Thomas, C.R., Jr, Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414) (2012) J. Thorac. Oncol., 7 (May (5)), pp. 906-912; Tong, C.C., Ko, E.C., Sung, M.W., Phase II trial of concurrent sunitinib and image- guided radiotherapy for oligometastases (2012) PLoS One, 7 (6); Topalian, S.L., Drake, C.G., Pardoll DM: targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity (2012) Curr. Opin. Immunol., 24, pp. 207-212; Triggiani, L., Alongi, F., Buglione, M., Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study (2017) Br. J. Cancer, 116 (12), pp. 1520-1525; Trino, E., Mantovani, C., Badellino, S., Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases (2017) Expert Rev. Anticancer Ther., 17 (April (4)), pp. 347-356; Trotti, A., Harris, J., Gillison, M., NRG-RTOG 1016: phase III trial comparing Radiation/Cetuximab to Radiation/Cisplatin in HPV-related Cancer of the oropharynx (2018) Int J Radiat Oncol Biol Phys. Supplement; Valabrega, G., Montemurro, F., Aglietta, M., Trastuzumab: mechanism of action, resistance and future perspectives in HER2- overexpressing breast cancer (2007) Ann. Oncol., 1, p. 17; Valentini, V., De Paoli, A., Gambacorta, M.A., Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092) (2008) Int J Radiat Oncol BiolPhys., 72 (November (3)), pp. 644-649; van den Heuvel, M.M., Uyterlinde, W., Vincent, A.D., Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating (2014) Radiother. Oncol., 110 (January (1)), pp. 126-131; Velenik, V., Ocvirk, J., Music, M., Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study (2011) Radiat. Oncol., 6 (August), p. 105; Verstraete, M., Debucquoy, A., Dekervel, J., Combining bevacizumab and chemoradiation in rectal cancer. Translational results of the AXEBeam trial (2015) Br. J. Cancer, 112 (April (8)), pp. 1314-1325; Viloria-Petit, A., Crombet, T., Jothy, S., Acquired resistance to the antitumor effect of epidermal growth factor receptor blocking antibodies in vivo: a role for altered tumor angiogenesis (2001) Cancer Res., 61, pp. 5090-5101; Vivaldi, C., Buccianti, G., Musettini, F., TRUST: phase II trial of induction chemotherapy with FOLFOXIRI + Bevacizumab followed by chemo-radiotherapy + Bevacizumab and surgery in locally advanced rectal carcinoma (2016) Ann. Oncol., 27 (October (Suppl_6)); Walraven, I., van den Heuvel, M., van Diessen, J., Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab (2016) Radiother. Oncol., 118 (March (3)), pp. 442-446; Wang, Z., Zhu, X.X., Wu, X.H., Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer (2014) Am. J. Clin. Oncol., 37 (April (2)), pp. 148-153; Waterhouse, P., Penninger, J.M., Timms, E., Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 (1995) Science, 270, pp. 985-988; Weiner, L.M., Adams, G.P., New approaches to antibody therapy (2000) Oncogene, 19, pp. 6144-6151; Weis, S.M., Cheresh, D.A., Tumor angiogenesis: molecular pathways and therapeutic targets (2011) Nat. Med., 17 (11), pp. 1359-1370; Welsh, J.W., Komaki, R., Amini, A., Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer (2013) J. Clin. Oncol., 31 (March (7)), pp. 895-902; Wirsching, H.G., Tabatabai, G., Roelcke, U., Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial (2018) Ann. Oncol., 29 (June (6)), pp. 1423-1430; Wilhelm, S., Carter, C., Lynch, M., Discovery and development of sorafenib: a multikinase inhibitor for treating cancer (2006) Nat. Rev. Drug Discov., 5 (10), pp. 835-844; Wellbrock, C., Karasarides, M., Marais, R., The RAF proteins take centre stage (2004) Nat. Rev. Mol. Cell Biol., 5, pp. 875-885; Willett, C.G., Duda, D.G., di Tomaso, E., Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study (2009) J. Clin. Oncol., 27 (June (18)), pp. 3020-3026; Yang, Q., Guan, K.-L., Expanding mTOR signaling (2007) Cell Res., 17, pp. 666-681; Yao, M., Woods, C., Lavertu, P., Phase II study of erlotinib and docetaxel with concurrent intensity-modulated radiotherapy in locally advanced head and neck squamous cell carcinoma (2016) Head Neck, 38 (April (Suppl 1)), pp. E1770-E1776; Zhang, H.P., Takayama, K., Su, B., Effect of sunitinib combined with ionizing radiation on endothelial cells (2011) J. Radiat. Res., 52, pp. 1-8; Zhang, Y., Wang, L., Li, Y., Protein expression of programmed death 1 ligand1 and ligand2 independently predict poor prognosis in surgically resected lung adenocarcinoma (2014) Onco. Ther., 7, pp. 567-573; Zhao, C., Lin, L., Liu, J., A phase II study of concurrent chemoradiotherapy and erlotinib for inoperable esophageal squamous cell carcinoma (2016) Oncotarget., 7 (August (35)), pp. 57310-57316; Zhuang, H., Yuan, Z., Wang, J., Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma (2013) Drug Des. Devel. Ther., 7 (October), pp. 1179-1186; Zwolak, P., Jasinski, P., Terai, K., Addition of receptor tyrosine kinase inhibitor to radiation increases tumour control in an orthotopic murine model of breast cancer metastasis in bone (2008) Eur. J. Cancer, 44, pp. 2506-2517

PY - 2019

Y1 - 2019

N2 - Over the past century, technologic advances have promoted the evolution of radiation therapy into a precise treatment modality allowing for the maximal administration of dose to tumors while sparing normal tissues. In parallel with this technological maturation, the rapid expansion in understanding the basic biology and heterogeneity of cancer has led to the development of several compounds that target specific pathways. Many of them are in advanced steps of clinical development for combination treatments with radiotherapy, and can be incorporated into radiation oncology practice for a personalized approach to maximize the therapeutic gain. This review describes the rationale for combining novel agents with radiation, and provides an overview of the current landscape focused on treatment efficacy. © 2018 Elsevier B.V.

AB - Over the past century, technologic advances have promoted the evolution of radiation therapy into a precise treatment modality allowing for the maximal administration of dose to tumors while sparing normal tissues. In parallel with this technological maturation, the rapid expansion in understanding the basic biology and heterogeneity of cancer has led to the development of several compounds that target specific pathways. Many of them are in advanced steps of clinical development for combination treatments with radiotherapy, and can be incorporated into radiation oncology practice for a personalized approach to maximize the therapeutic gain. This review describes the rationale for combining novel agents with radiation, and provides an overview of the current landscape focused on treatment efficacy. © 2018 Elsevier B.V.

KW - abiraterone

KW - anastrozole

KW - antineoplastic agent

KW - apalutamide

KW - bevacizumab

KW - capecitabine

KW - cetuximab

KW - cisplatin

KW - docetaxel

KW - enzalutamide

KW - erlotinib

KW - everolimus

KW - exemestane

KW - gemcitabine

KW - imatinib

KW - letrozole

KW - nicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferase inhibitor

KW - oxaliplatin

KW - paclitaxel

KW - panitumumab

KW - pertuzumab

KW - sonidegib

KW - sorafenib

KW - sunitinib

KW - temozolomide

KW - trastuzumab

KW - unindexed drug

KW - veliparib

KW - vemurafenib

KW - vismodegib

KW - radiosensitizing agent

KW - basal cell carcinoma

KW - brain metastasis

KW - breast cancer

KW - cancer combination chemotherapy

KW - cancer control

KW - cancer radiotherapy

KW - cancer survival

KW - carcinomatous peritonitis

KW - clinical effectiveness

KW - digestive system cancer

KW - drug efficacy

KW - drug safety

KW - esophageal adenocarcinoma

KW - gastrointestinal stromal tumor

KW - glioblastoma

KW - glioma

KW - head and neck squamous cell carcinoma

KW - human

KW - human epidermal growth factor receptor 2 negative breast cancer

KW - human epidermal growth factor receptor 2 positive breast cancer

KW - kidney cancer

KW - kidney metastasis

KW - melanoma

KW - metastatic breast cancer

KW - metastatic colorectal cancer

KW - muscle invasive bladder cancer

KW - non small cell lung cancer

KW - nonhuman

KW - pancreas cancer

KW - pancreas islet cell tumor

KW - phase 2 clinical trial (topic)

KW - phase 3 clinical trial (topic)

KW - prostate cancer

KW - rectum cancer

KW - renal cell carcinoma

KW - Review

KW - solid malignant neoplasm

KW - treatment failure

KW - chemoradiotherapy

KW - Italy

KW - neoplasm

KW - treatment outcome

KW - Chemoradiotherapy

KW - Humans

KW - Neoplasms

KW - Radiation-Sensitizing Agents

KW - Treatment Outcome

U2 - 10.1016/j.critrevonc.2018.11.005

DO - 10.1016/j.critrevonc.2018.11.005

M3 - Article

VL - 134

SP - 87

EP - 103

JO - Crit. Rev. Oncol. Hematol.

JF - Crit. Rev. Oncol. Hematol.

SN - 1879-0461

ER -

Access to Document

10.1016/j.critrevonc.2018.11.005

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85059913505&doi=10.1016%2fj.critrevonc.2018.11.005&partnerID=40&md5=b6d79ec9b087bf28678292ab15d1a552

Projects

I.E.O. - IMAGING E TRATTAMENTI LOCO-REGIONALI INNOVATIVI

Project: Other project

Combination of novel systemic agents and radiotherapy for solid tumors – part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy: Critical Reviews in Oncology/Hematology

Abstract

Fingerprint

Keywords

Cite this

Access to Document

Related content

Projects

I.E.O. - IMAGING E TRATTAMENTI LOCO-REGIONALI INNOVATIVI